Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain

Description

Prospective, single-center that may go on to being multicenter, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.

Conditions

Hip Osteoarthritis

Talk to us

Study Overview

On this page

Study Details

Study overview

Prospective, single-center that may go on to being multicenter, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.

The Efficacy of Platelet Rich Plasma Compared with Corticosteroid Injections for the Treatment of Pain Associated with Hip Osteoarthritis

Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain

Condition
Hip Osteoarthritis
Intervention / Treatment

-

Contacts and Locations

Baltimore

Sinai Hospital of Baltimore, Baltimore, Maryland, United States, 21215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Provision of signed and dated informed consent form
  • * Stated willingness to comply with all study procedures and availability for the duration of the study
  • * Male or female, aged 21-80 years
  • * Radiographic diagnosis of Kellgren-Lawrence (KL) grade of II or III Hip osteoarthritis
  • * Indicated for a Hip injection to treat Hip OA symptoms
  • * Any injections into the target Hip within three months
  • * Current overlying skin infection
  • * Current or previous diagnosis of "chronic pain"
  • * Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.)
  • * Allergy to any potential ingredients or medications utilized in any of the two groups
  • * Treatment with another investigational drug or other intervention for pain
  • * Diagnosis of Diabetes Mellitus
  • * If female, pregnant or planning to be pregnant within the following 3 months or study duration
  • * Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation

Ages Eligible for Study

21 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

LifeBridge Health,

Study Record Dates

2025-12-01